↑ 疾患リストへ ← 戻る

 25. 進行性多巣性白質脳症 [臨床試験数:16,薬物数:26(DrugBank:20),標的遺伝子数:7,標的パスウェイ数:34] 

Searched query = "Progressive multifocal leukoencephalopathy", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04091932August 20, 201930 September 2019Treatment of PD-1 Inhibitor in AIDS-associated PMLThe Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Progressive Multifocal Leukoencephalopathy (PML): A One-center, Single-arm and Prospective StudyProgressive Multifocal Leukoencephalopathy;AIDSDrug: PembrolizumabFirst Affiliated Hospital of Zhejiang UniversityRecruiting18 Years65 YearsAll10Phase 2China
2NCT03399981January 24, 201824 June 2019Tysabri Observational Cohort Study - Multiple Sclerosis (MS) RegistriesAn Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With TysabriProgressive Multifocal LeukoencephalopathyBiological: TysabriBiogenNot recruitingN/AN/AAll72600N/AUnited States
3JPRN-UMIN0000221512016/04/302 April 2019The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathyThe efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathymefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manthsDepartment of Neurology, Shimane University HospitalRecruiting20years-oldNot applicableMale and Female5Not selectedJapan
4JPRN-UMIN0000237522016/04/142 April 2019Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insuranceprogressive multifocal leukoencephalopathyOral mefloquine hydrochloride 275mg once a day at first 3 days.
Since second week, 275mg in each week oral intake until 6 months
Nagoya City UniversityNot RecruitingNot applicableNot applicableMale and Female1Not applicableJapan
5NCT02694783March 28, 201611 March 2019Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-CellsA Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-cellsLeukoencephalopathyBiological: PyVST;Other: No InterventionNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting18 YearsN/AAll60Early Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01970410October 201311 June 2018Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to TeriflunomideSwitching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective?Multiple SclerosisDrug: teriflunomideMultiple Sclerosis Center of Northeastern New YorkProvidence Multiple Sclerosis CenterNot recruiting21 Years60 YearsAll70Phase 4United States
7EUCTR2012-000725-41-GB22/01/201310 March 2014A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal LeukoencephalopathyA randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy. - INVICTUSHIV-infected patients with Progressive Multifocal Leukoencephalopathy
MedDRA version: 15.0 Level: PT Classification code 10036807 Term: Progressive multifocal leukoencephalopathy System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
Product Name: Recombinant human interleukin-7
Product Code: CYT107
Pharmaceutical Form: Solution for injection
INN or Proposed INN: N/A
CAS Number: N/A
Current Sponsor code: CYT107
Other descriptive name: Recombinant human interleukin-7
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 4-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Cytheris S.A.Not RecruitingFemale: yes
Male: yes
57Phase 2bUnited States;European Union;Spain;Italy;Switzerland;United Kingdom
8NCT01211665September 201019 October 2017Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on NatalizumabImmune Reconstitution Inflammatory Syndrome;Leukoencephalopathy, Progressive MultifocalDrug: Methylprednisolone;Drug: PrednisoloneBiogenElan PharmaceuticalsNot recruiting18 YearsN/AAll3Phase 4United States;Germany
9EUCTR2008-001314-24-GB02/01/200919 March 2012A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Progressive Multifocal Leukoencephalopathy (PML)
MedDRA version: 9.1 Level: LLT Classification code 10036807 Term: Progressive multifocal leukoencephalopathy
Trade Name: Lariam
Product Name: Mefloquine
Product Code: 111JC101
Pharmaceutical Form: Tablet
INN or Proposed INN: MEFLOQUINE
CAS Number: 53230107
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-
Biogen Idec LtdNot RecruitingFemale: yes
Male: yes
60United Kingdom;France;Spain;Italy
10NCT00746941January 200919 October 2017Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)Progressive Multifocal LeukoencephalopathyDrug: mefloquineBiogenElan PharmaceuticalsNot recruiting18 Years75 YearsAll37Phase 1/Phase 2United States;Brazil;Germany;Italy;Spain;Australia;France;Puerto Rico;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00120367April 200519 February 2015Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 TrialLeukoencephalopathy, Progressive Multifocal;HIV InfectionsDrug: Enfuvirtide;Drug: Tenofovir-EmtricitabineFrench National Agency for Research on AIDS and Viral HepatitisHoffmann-La Roche;Gilead SciencesNot recruiting18 YearsN/ABoth30Phase 2France
12NCT00000945November 199919 February 2015A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS PatientsA Pilot Study of the Effect of Cidofovir for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Subjects With Acquired Immunodeficiency Syndrome (AIDS)HIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: Cidofovir;Drug: ProbenecidNational Institute of Allergy and Infectious Diseases (NIAID)Not recruiting18 YearsN/ABoth24N/AUnited States
13NCT00001048February 199819 February 2015Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected PatientsA Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infected SubjectsHIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: Filgrastim;Drug: Cytarabine;Drug: Zidovudine;Drug: Zalcitabine;Drug: DidanosineNational Institute of Allergy and Infectious Diseases (NIAID)Bristol-Myers Squibb;UpjohnNot recruiting18 Years65 YearsBoth90Phase 2United States
14NCT00002270October 199719 February 2015A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 InfectionA Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 InfectionHIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: Interferon alfa-2b;Drug: ZidovudineUniversity of MiamiNot recruiting18 Years65 YearsBothN/AUnited States
15NCT00002274October 199719 February 2015A Study of ddI in Patients With AIDS Who Become Sicker While Taking ZidovudineAn Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir)HIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: DidanosineBristol-Myers SquibbNot recruiting12 YearsN/ABothN/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00002395June 199619 February 2015Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal LeukoencephalopathyHIV Infections;Leukoencephalopathy, Progressive MultifocalDrug: TopotecanSmithKline BeechamNot recruiting18 YearsN/ABoth54Phase 2United States

先頭へ